89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Exclusion criteria

• . Have been administered any radionuclide within 10 half-lives (of the radionuclide) prior to the intended administration of 89Zr-girentuximab (i.e., within 10 half-lives of Day 0);
• . Have been exposed to any CAIX targeting compound (diagnostic/therapeutic) in the prior 3 months;
• . Have any serious non-malignant disease (e.g., psychiatric, infectious, autoimmune or metabolic) that may interfere with the objectives of the study or with the safety or compliance of the participant, as judged by the Investigator;
• . Have any clinically significant abnormalities detected during screening laboratory tests or physical exam that, in the opinion of the Investigator, would adversely affect the participant's ability to participate in the study;
• . Have a mental impairment that may compromise the ability to give Informed Consent and comply with the requirements of the study;
• . Have been exposed to any antineoplastic treatment from Day 0 (89Zr-girentuximab dosing) to completion of 89Zr-girentuximab PET/CT imaging (Day 5 ± 2 days);
• . Be a female who is pregnant or breastfeeding;
• . Have a known allergy, hypersensitivity, or intolerance to girentuximab, desferrioxamine (DFO), or any of the components of the investigational agent;